RhumbLine Advisers
GTBP icon

RhumbLine Advisers’s GT Biopharma GTBP Stock Holding History

RhumbLine Advisers’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-536
Closed -$46K – 3150
2022
Q1 		$46K Sell
536
-20
-4% -$1.76K ﹤0.01% 2980
2021
Q4 		$51K Hold
556
– – ﹤0.01% 2979
2021
Q3 		$112K Sell
556
-65
-10% -$19.6K ﹤0.01% 2983
2021
Q2 		$289K Buy
+621
New +$258K ﹤0.01% 2803

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's GTBP Position: Q2 2022 in Review

RhumbLine Advisers sold out of GT Biopharma (GTBP) in Q2 2022, closing a stake of 536 shares — an estimated $46K sold.

RhumbLine Advisers first reported a position in GTBP in Q2 2021 and held it in 4 quarters. The position peaked at $289K in Q2 2021. 47 funds tracked by Wall St. Rank hold GTBP as of Q2 2022.

  • RhumbLine Advisers reported no remaining GT Biopharma position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 536 GT Biopharma shares in Q2 2022, an estimated $46K.
  • RhumbLine Advisers first reported a position in GT Biopharma in Q2 2021 and held it in 4 quarters.
  • RhumbLine Advisers's GT Biopharma position peaked at $289K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.